Trial reportDisease markers2021
Elevated Serum Small Dense Low-Density Lipoprotein Cholesterol May Increase the Risk and Severity of Coronary Heart Disease and Predict Cardiovascular Events in Patients with Type 2 Diabetes Mellitus.
Trial report in Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Oxidative Stress, Antioxidant Capacity, Dyslipidemia and Cardiovascular Risk in Sickle Cell Disease: A Systematic Review and Meta-Analysis.TheScientificWorldJournal · 2026Pooled it
- Reconceptualizing Dyslipidemia: Diversity of Lipid Imbalances and Their Clinical Implications; A Narrative Review.Health science reports · 2026Article
- Role of combined serum homocysteine and small dense LDL-C in predicting cardiovascular events in obesity: a retrospective clinical study.BMC cardiovascular disorders · 2026Article
- Estimation of small dense low-density lipoprotein cholesterol and cardiometabolic multimorbidity risk in middle-aged and elderly Chinese: findings from a nationwide prospective cohort.BMC cardiovascular disorders · 2026Article
- SdLDL‑C/LDL‑C discordance as a practical surrogate for triglyceride‑associated cardiovascular risk: identification of at‑risk lipid phenotypes in the CHARLS prospective cohort.Lipids in health and disease · 2026Article
- Small dense LDL: An underestimated driver of atherosclerosis (Review).Molecular medicine reports · 2025Review
- Association of estimated small dense low-density lipoprotein cholesterol with diabetes mellitus: a large-scale multicenter retrospective cohort study.BMC endocrine disorders · 2025Article
- Suboptimal Control of Small Dense Low-Density Lipoprotein Cholesterol Is Associated With Coronary Plaque Progression: An Intravascular Ultrasound Study.Journal of the American Heart Association · 2025Article
- Article
- Nrf2 Signaling Pathway as a Key to Treatment for Diabetic Dyslipidemia and Atherosclerosis.International journal of molecular sciences · 2024Review
- Identification of Hub Genes and Immune Infiltration in Coronary Artery Disease: A Risk Prediction Model.Journal of inflammation research · 2024Article
- Correlation Between Glycolipid Metabolism Levels and Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- The Relationship Between Small Dense Low-Density Lipoprotein Cholesterol and Metabolic Syndrome.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Precision subclassification of type 2 diabetes: a systematic review.Communications medicine · 2023Article
- The LDL-C/ApoB ratio predicts cardiovascular and all-cause mortality in the general population.Lipids in health and disease · 2023Article
- Dyslipidemia Among Diabetes Mellitus Patients: A Case-Control Study From a Tertiary Care Hospital in South India.Cureus · 2023Article
- Diabetic dyslipidemia impairs coronary collateral formation: An update.Frontiers in cardiovascular medicine · 2022Review
- Clinical Nomogram to Predict Major Adverse Cardiac Events in Acute Myocardial Infarction Patients within 1 Year of Percutaneous Coronary Intervention.Cardiovascular therapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary heart disease (CHD) is a common and severe complication in type 2 diabetes mellitus (T2DM) patients. Increased amount of circulatory small dense low-density lipoprotein cholesterol (sdLDL-C) particles is known to be a sign of dyslipidemia and can result in atherosclerosis. However, the association between serum sdLDL-C levels and CHD in T2DM patients remains unclear.
methodsA total of 3684 T2DM patients who received selective coronary angiography (CAG) were selected. For analyzing the association between sdLDL-C and CHD severity in T2DM, the patients with CHD were further divided into four subgroups according to the quartiles of sdLDL-C. A multivariate logistic regression was used for analyzing the risks and severity of CHD. A total of 3427 patients with continuous stable CHD were recruited and followed up for 5 years.
resultsSerum sdLDL-C levels in the CHD group were significantly increased compared with those in the non-CHD group [0.80 (0.49) mmol/L vs. 0.70 (0.30) mmol/L,
conclusionIn T2DM patients, elevated serum sdLDL-C may increase the severity of CHD and predict cardiovascular events in the future. Therefore, serum sdLDL-C may be a potential biomarker for the surveillance of CHD in T2DM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.